Roche: Zelboraf Study Failed to Meet Endpoint

Features Dow Jones Newswires

Swiss healthcare company Roche Holding AG (ROG.EB) said Monday that the phase III study of Zelboraf used for treatment of melanoma, a type of skin cancer, didn't meet its primary endpoint.

Continue Reading Below

The phase III BRIM8 study was designed to investigate the efficacy and safety of Zelboraf in after-surgery treatment of people with completely resected, BRAF V600 mutation-positive melanoma.

"While results in people with stage IIIC melanoma were not what we had hoped, the reduction in the risk of recurrence in people with stage IIC-IIIB disease is encouraging and suggests Zelboraf may play a role in this earlier setting," said Chief Medical Officer and Head of Global Product Development Sandra Horning.

Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

September 11, 2017 02:11 ET (06:11 GMT)